{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T06:22:08Z","timestamp":1768803728996,"version":"3.49.0"},"reference-count":38,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This open\u2010label, phase Ib study (NCT02346370) assessed the effect of pegvorhyaluronidase alfa (PVHA; PEGPH20) on the plasma pharmacokinetics (PKs) and safety of docetaxel in 15 patients with stage IIIB\/IV non\u2010small cell lung cancer (NSCLC). The docetaxel PK profile from this study was consistent with simulations from a published docetaxel population PK model, and did not demonstrate an effect of PVHA on docetaxel PK. A maximum a posteriori Bayesian fit of the literature PK model to the docetaxel PK appeared unbiased. Adverse events (AEs) were generally consistent with previous reports for docetaxel monotherapy in NSCLC, except for higher incidence of musculoskeletal events, including myalgias, with PVHA plus docetaxel. The most common AEs were fatigue (87%), muscle spasms (60%), and myalgia (53%). Four patients experienced thromboembolic events (27%), three leading to treatment discontinuation. PVHA appeared to demonstrate an acceptable safety profile when given with docetaxel without significantly changing the plasma PK of docetaxel in patients with stage IIIB\/IV NSCLC.<\/jats:p>","DOI":"10.1111\/cts.13041","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T08:37:55Z","timestamp":1620895075000},"page":"1875-1885","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non\u2010small cell lung cancer"],"prefix":"10.1111","volume":"14","author":[{"given":"Thomas","family":"Heineman","sequence":"first","affiliation":[{"name":"Halozyme Therapeutics, Inc. San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Baumgart","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center Rochester New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charvi","family":"Nanavati","sequence":"additional","affiliation":[{"name":"Halozyme Therapeutics, Inc. San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nash","family":"Gabrail","sequence":"additional","affiliation":[{"name":"Gabrail Cancer Center Canton Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"Van Wart","sequence":"additional","affiliation":[{"name":"Enhanced Pharmacodynamics, LLC Buffalo New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald E.","family":"Mager","sequence":"additional","affiliation":[{"name":"Enhanced Pharmacodynamics, LLC Buffalo New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Maneval","sequence":"additional","affiliation":[{"name":"Halozyme Therapeutics, Inc. San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas M.","family":"Fathallah","sequence":"additional","affiliation":[{"name":"Halozyme Therapeutics, Inc. San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose E.","family":"Sekulovich","sequence":"additional","affiliation":[{"name":"Halozyme Therapeutics, Inc. San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2010.11.017"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302529"},{"key":"e_1_2_12_4_1","first-page":"150","article-title":"High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer","volume":"60","author":"Anttila MA","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64757-8"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00448-2"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MP.0000051582.75890.2D"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000140"},{"key":"e_1_2_12_9_1","first-page":"3503","article-title":"Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase","volume":"20","author":"Brekken C","year":"2000","journal-title":"Anticancer Res"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2016.03.040"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.01.007"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0580"},{"key":"e_1_2_12_13_1","first-page":"1203","article-title":"Effective targeting of the tumor microenvironment for cancer therapy","volume":"32","author":"Jiang P","year":"2012","journal-title":"Anticancer Res"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/817613"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0214"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0470"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.327"},{"key":"e_1_2_12_18_1","unstructured":"FathallahAM Fang S Caster CL et al.Biodistribution of radio\u2010labeled recombinant human hyaluronidase PH20 (rHuPH20) and PEGylated rHuPH20 in mice. American Association of Pharmaceutical Scientists\u2010National Biotechnology Conference 2015.2015: Abstract W3048."},{"key":"e_1_2_12_19_1","first-page":"175","volume-title":"Polymer\u2010Protein Conjugates. From PEGylation and Beyond","author":"Maneval DC","year":"2019"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.e15005"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.9564"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00590"},{"key":"e_1_2_12_23_1","unstructured":"Sanofi\u2010Aventis.TAXOTERE\u00ae(docetaxel) for injection. Prescribing Information.2015. September 27 2018."},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2014.34.177"},{"key":"e_1_2_12_26_1","unstructured":"World Health Organization.Cancer fact sheet.2018. Available at:http:\/\/www.who.int\/newsroom\/fact\u2010sheets\/detail\/cancer"},{"key":"e_1_2_12_27_1","unstructured":"BlouwB Marella M Garrovillo S et al.Evaluation of HA levels and response to docetaxel \u00b1 PEGPH20 therapy in nude mice bearing PDx non\u2010small cell lung cancer (NSCLC).European Organisation for Research and Treatment of Cancer 2015 March 12\u201013; abstract IBCD15\u201008.2015."},{"key":"e_1_2_12_28_1","unstructured":"Bristol\u2010Myers\u2010Squibb.Opdivo (nivolumab) US Prescribing Information.2015. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125527s000lbl.pdf"},{"key":"e_1_2_12_29_1","unstructured":"Merck.Keytruda pembrolizumab US Prescribing Information.2017. Available at:http:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf"},{"key":"e_1_2_12_30_1","unstructured":"Data on File. Microconstants Inc.Partial validation of a method for the determination of docetaxel in human K3EDTA plasma using high\u2010performance liquid chromatography with mass spectrometric detection. Method validation report MC15B\u20100030.2016; September 15 2020."},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02353487"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.12.2354"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.10.2095"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.6065"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e318219863b"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.137"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03621.x"},{"key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"P1\u201003\u201009","DOI":"10.1158\/1538-7445.SABCS15-P1-03-09","article-title":"Pegylated recombinant human hyaluronidase PH20 (PEGPH20) enhances efficacy of eribulin mesylate (HALAVEN\u00ae) in triple negative breast cancer xenografts","volume":"76","author":"Bahn JD","year":"2016","journal-title":"Cancer Res"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2010"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13041","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.13041","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T08:57:51Z","timestamp":1692953871000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1111\/cts.13041"],"URL":"https:\/\/doi.org\/10.1111\/cts.13041","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"assertion":[{"value":"2020-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}